Bibliographic Info
GuidelineUpdated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics.
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
We recommend the use of the following pangenotypic DAA regimens in younger children (3–5 years) with chronic hepatitis C infection, regardless of stage of disease: sofosbuvir/daclatasvir (Most widely used regimen in adults due to availability of quality-assured, low-cost generics) for 12 weeks (In those without cirrhosis. Treatment for 24 weeks in those who are treatment-experienced or with compensated cirrhosis), sofosbuvir/velpatasvir for 12 weeks, glecaprevir/pibrentasvir for eight weeks
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Updated recommendations on treatment of adolescents and children with chronic HCV infection: policy brief.
Year2022
InstitutionWorld Health Organization